) recently announced positive results from a phase II study
(n=46) on its candidate HSPPC-96 (prophage series G-100) in
combination with the current standard of care in newly diagnosed
glioblastomamultiforme (GBM) patients.
Results from the study revealed that patients treated with the
combination therapy showed a significant increase in progression
free survival (PFS) in comparison to patients treated with
current standard of care alone. Moreover, the median overall
survival (OS) rate, the primary objective of the study, was 23.3
months in patients treated with the HSPPC-96 combination in
comparison to 14.6 months in patients under current standard of
Following the positive results, Agenus now plans to hold an end
of phase II meeting with the U.S. Food and Drug Administration
(FDA) to discuss about initiating a phase III study on the
HSPPC-96 vaccine in patients with newly diagnosed GBM. The
company plans to seek approval for the brain cancer vaccine based
on the phase III study.
We are encouraged by the company's progress on HSPPC-96. We note
that Agenus has another prophage series vaccine, G-200, in its
pipeline. The candidate is currently in a phase II study in
) Avastin in patients with surgically resectable recurrent
However, the oncology market currently looks extremely crowded
with the presence of big companies like Roche and
Agenus presently carries a Zacks Rank #4 (Sell). Meanwhile,
stocks such as
) carrying a Zacks Rank #1 (Strong Buy) look more attractive.
AGENUS INC (AGEN): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.